The dysregulation of TGF-β signaling is implicated in cancer progression, and CBP/p300’s involvement in modulating SMAD3-dependent transcription suggests a therapeutic avenue for targeting cancers with altered TGF-β activity. This evidence concerns the gene EP300 and cancer.